Invicro
21
2
2
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
9.5%
2 terminated/withdrawn out of 21 trials
89.5%
+3.0% vs industry average
0%
0 trials in Phase 3/4
24%
4 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
Role: lead
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
Role: lead
PET Study of Repeated ASN51 in Healthy Volunteers
Role: collaborator
Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.
Role: collaborator
Plasma P-tau2017 and Quantitative Amyloid PET Imaging
Role: lead
Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
Role: lead
Evaluation of [18F]APN-1607 as a PET Biomarker
Role: lead
Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain
Role: lead
Safety and Targeting of Anti-hk2 Antibody in mCRPC
Role: collaborator
131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma
Role: collaborator
Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444
Role: lead
A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants
Role: collaborator
Do Adolescents and Adults Differ in Their Acute Response to Cannabis?
Role: collaborator
TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort
Role: collaborator
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
Role: lead
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
Role: lead
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
Role: lead
Assessment of the Biodistribution and Safety of [18F]MNI-1054
Role: lead
Assessment of [18F]MNI-1054 as a Marker for LSD1
Role: lead
D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562
Role: lead